Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma
نویسندگان
چکیده
•Describes the conversion of a gastric band into an intraperitoneal chemotherapy port•Removal of band is important for cytoreduction and preventing future complications.•Conversion of the gastric band to an IP port saved the patient the need for a new intraperitoneal port.•Rising obesity may see more patients with ovarian cancer involving gastric bands.•Consider ovarian pathology in women with abdominal symptoms after bariatric surgery.
منابع مشابه
Treatment of ovarian cancer with intraperitoneal chemotherapy.
In early 2006, the National Cancer Institute (NCI) issued a Clinical Announcement suggesting that intraperitoneal (IP) chemotherapy should become the standard of care for patients with newly diagnosed stage III optimally debulked epithelial ovarian cancer. IP chemotherapy, the administration of chemotherapy or biologic therapy via catheter into the peritoneal space, is new to many healthcare pr...
متن کاملKCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer
Approximately 50-75% of patients with serous ovarian carcinoma (SOC) experience recurrence within 18 months after first-line treatment. Current clinical indicators are inadequate for predicting the risk of recurrence. In this study, we used 7 publicly available microarray datasets to identify gene signatures related to recurrence in optimally debulked SOC patients, and validated their expressio...
متن کاملIs there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?
AIM The effect of systematic retroperitoneal lymphadenectomy (SRL) remains controversial in patients with advanced epithelial ovarian cancer (aEOC) who are optimally debulked. MATERIAL AND METHODS Demographic and clinicopathologic data were obtained from the Tokai Ovarian Tumor Study Group between 1986 and 2009. All patients were divided into two groups. Group A (n = 93): (i) patients did not...
متن کاملEndometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
UNLABELLED Aromatase inhibitors have not been adequately assessed in treatment of ovarian cancer. The aromatase inhibitor letrozole (2.5 mg daily) was administered in 2 cases of advanced endometrioid ovarian cancer with positive estrogen receptor. CASE 1: A 52-year-old woman with a grade 2-3, stage iiic endometrioid ovarian cancer was optimally debulked and received 6 cycles of intravenous pacl...
متن کاملImplementation of intraperitoneal chemotherapy for the treatment of ovarian cancer.
In January 2006, a clinical announcement made by the National Cancer Institute suggested that intraperitoneal chemotherapy become standard care for patients with newly diagnosed stage III, optimally debulked epithelial ovarian cancer. Intraperitoneal chemotherapy is new to many healthcare providers (i.e., physicians, nurses, and pharmacists). This article will discuss how to implement intraperi...
متن کامل